ArticleFASEB bioAdvances2025
Effects of Bone Morphogenetic Protein-7 on Steroid-Induced Extracellular Matrix Accumulation in Human Trabecular Meshwork Cells.
Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term steroid use, though essential for treating eye diseases, can cause increased intraocular pressure (IOP) in susceptible individuals and may lead to steroid-induced glaucoma in a subset of patients. This study investigated the effect of bone morphogenetic protein-7 (BMP-7) on steroid-induced extracellular matrix (ECM) synthesis in human trabecular meshwork (TM) cells. We sought to explore the potential of BMP-7 as a protective agent against steroid-induced ECM accumulation in the TM. Human TM cells (HTMCs) were treated with either steroids alone or a combination of steroids and BMP-7 to compare their effects on ECM production. BMP-7, known for its transforming growth factor beta (TGF-β) antagonistic properties, was administered using a micellized protein transduction domain (mPTD)-fused BMP-7 polypeptide to enhance activity. Gene expression analysis was conducted to identify specific genes involved in ECM regulation. BMP-7 effectively inhibited steroid-induced ECM accumulation in HTMCs. There was a significant reduction in ECM production in the steroid and BMP-7 co-treated group compared with that in the steroid-only group. Furthermore, several genes involved in ECM regulation were identified in the co-treatment, underscoring BMP-7's potential role in modulating ECM metabolism. These findings demonstrate that BMP-7 exerts protective, anti-fibrotic effects in HTMCs by inhibiting steroid-induced ECM synthesis. BMP-7 may serve as a promising therapeutic target for preventing or treating steroid-induced glaucoma by maintaining normal aqueous humor outflow and preventing IOP elevation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.